<DOC>
	<DOCNO>NCT00260481</DOCNO>
	<brief_summary>The purpose study assess efficacy PROMETA pharmacotherapy compare placebo initiate abstinence prevent relapse methamphetamine use treatment-seeking individual meet criterion methamphetamine abuse . It hypothesize individual assign receive PROMETA pharmacotherapy , compare placebo , demonstrate significantly few less intense withdrawal symptom , day abstinent methamphetamine use , few relapse methamphetamine use assessed self-report drug use verify urine sample .</brief_summary>
	<brief_title>Prometa Pharmacotherapy Methamphetamine Dependence</brief_title>
	<detailed_description>Using double-blind placebo design , effectiveness Prometa protocol methamphetamine dependence investigate compare placebo condition . The procedure utilizes combination medication deliver orally infusion control medical setting . Participants randomly assign active medication placebo condition , receive medication 40 day , include two inpatient hospitalization phase three day . All participant also receive once-weekly psychosocial cognitive-behavioral therapy throughout 106 day study duration . A variety data collect throughout study , include psychological , cognitive , medical , laboratory assessment .</detailed_description>
	<mesh_term>Substance-Related Disorders</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Be least 18 yearsofage ; Have DSMIVTR diagnosis methamphetamine abuse dependence determine SCID ; Be seek treatment methamphetamine abuse dependence ; Be able understand , understood , provide write informed consent ; If female child bear potential , agree use approve method birth control surgically sterile ; Have complete psychological assessment ; Have use methamphetamine least 4 last 30 day . Have current dependence , define DSMIVTR criterion , psychoactive substance methamphetamine , alcohol , nicotine , marijuana physiological dependence alcohol require medical detoxification ( CIWAAR score â‰¥ 15 ) ; Be mandate court obtain treatment methamphetamineabuse dependence ; Be anyone , opinion investigator , would expect complete study protocol due probable incarceration relocation clinic area ; Have current previous psychiatric , neurological disorder include limited epilepsy absence seizure , faint spell , brain disease , dementia , disorder , opinion study physician require ongoing treatment would make study participation unsafe would make treatment compliance difficult . Have psychiatric disorder , assess SCID , neurological disorder include limited epilepsy absence seizure , brain disease , dementia disorder , opinion study physician , require ongoing treatment would make study participation unsafe would make treatment compliance difficult ; Have electroconvulsive therapy within past 3 month precede screening ; Have current suicidal ideation plan ( within past 30 day ) assess SCID ; Be pregnant lactating ; Have serious medical illness ( include , limited : uncontrolled hypertension , significant heart disease include myocardial infarction within one year enrollment , clinically significant cardiovascular abnormality ( ECG ) , hepatic , renal gastrointestinal disorder could result clinically significant alteration metabolism excretion study agent , potentially lifethreatening progressive medical illness addiction may compromise subject safety study conduct ) ; Have clinically significant abnormal laboratory value ; Benzodiazepine and/or similar sedativehypnotic anxiolytic use abuse within 15 day potential PROMETA Treatment ; Must habituate benzodiazepine must provide urine sample negative benzodiazepine ; Must take supratherapeutic dos zolpidem ( Ambien TM ) zaleplon ( Sonata TM ) ; Taking clonazepam ( Klonopin TM ) benzodiazepine ; Patients must take cyclic antidepressant , lithium , methylxanthines , isoniazid , propoxyphene , monoamine oxidase inhibitor , buproprion HCL , cyclosporine . Have AIDS ; Have active tuberculosis ( positive tuberculin test confirmatory diagnostic chest xray ) ; Have know suspect hypersensitivity PROMETA ; Have treat PROMETA reason currently past year ; Have disorder condition , opinion study physician , would make study participation difficult unsafe .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Methamphetamine Dependence</keyword>
	<keyword>Pharmacotherapy</keyword>
</DOC>